keyword
https://read.qxmd.com/read/38655625/assembly-of-glycopeptides-in-living-cells-resembling-viral-infection-for-cargo-delivery
#1
JOURNAL ARTICLE
Feng Tian, Ruo-Chen Guo, Chunxia Wu, Xin Liu, Zeyu Zhang, Yamei Wang, Hao Wang, Gongyu Li, Zhilin Yu
Self-assembly in living cells represents one versatile strategy for drug delivery; however, it suffers from the limited precision and efficiency. Inspired by viral traits, we here report a cascade targeting-hydrolysis-transformation (THT) assembly of glycosylated peptides in living cells holistically resembling viral infection for efficient cargo delivery and combined tumor therapy. We design a glycosylated peptide via incorporating a β-galactose-serine residue into bola-amphiphilic sequences. Co-assembling of the glycosylated peptide with two counterparts containing irinotecan (IRI) or ligand TSFAEYWNLLSP (PMI) results in formation of the glycosylated co-assemblies SgVEIP, which target cancer cells via β-galactose-galectin-1 association and undergo galactosidase-induced morphological transformation...
April 24, 2024: Angewandte Chemie
https://read.qxmd.com/read/38653245/integrated-drug-profiling-and-crispr-screening-identify-bcr-abl1-independent-vulnerabilities-in-chronic-myeloid-leukemia
#2
JOURNAL ARTICLE
Shady Adnan Awad, Olli Dufva, Jay Klievink, Ella Karjalainen, Aleksandr Ianevski, Paavo Pietarinen, Daehong Kim, Swapnil Potdar, Maija Wolf, Kourosh Lotfi, Tero Aittokallio, Krister Wennerberg, Kimmo Porkka, Satu Mustjoki
BCR::ABL1-independent pathways contribute to primary resistance to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) and play a role in leukemic stem cell persistence. Here, we perform ex vivo drug screening of CML CD34+ leukemic stem/progenitor cells using 100 single drugs and TKI-drug combinations and identify sensitivities to Wee1, MDM2, and BCL2 inhibitors. These agents effectively inhibit primitive CD34+ CD38- CML cells and demonstrate potent synergies when combined with TKIs...
April 10, 2024: Cell reports medicine
https://read.qxmd.com/read/38650632/activation-of-p53-signaling-and-regression-of-breast-and-prostate-carcinoma-cells-by-spirooxindole-benzimidazole-small-molecules
#3
JOURNAL ARTICLE
Assem Barakat, Saeed Alshahrani, Abdullah Mohammed Al-Majid, Abdullah Saleh Alamary, Matti Haukka, Marwa M Abu-Serie, Alexander Dömling, Luis R Domingo, Yaseen A M M Elshaier
This study discusses the synthesis and use of a new library of spirooxindole-benzimidazole compounds as inhibitors of the signal transducer and activator of p53, a protein involved in regulating cell growth and cancer prevention. The text includes the scientific details of the [3 + 2] cycloaddition (32CA) reaction between azomethine ylide 7a and ethylene 3a within the framework of Molecular Electron Density Theory. The mechanism of the 32CA reaction proceeds through a two-stage one-step process, with emphasis on the highly asynchronous transition state structure...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38646791/diagnosing-liposarcoma-on-peri-renal-mass-biopsy-a-clinicopathological-study-of-30-cases
#4
JOURNAL ARTICLE
Susan K Potterveld, Aysha Mubeen, William J Anderson, Michael R Clay, Melanie Bourgeau, Gregory W Charville, Ankur R Sangoi
AIMS: Classification of renal neoplasms on small tissue biopsies is in increasing demand, and maintaining broad differential diagnostic considerations in this setting is necessary. When evaluating a renal or perirenal tumour biopsy with sarcomatoid morphology, together with sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma as top diagnostic considerations, it is vital to additionally consider the possibility of well-differentiated and de-differentiated liposarcoma...
April 22, 2024: Histopathology
https://read.qxmd.com/read/38646431/case-report-navigating-treatment-pathways-for-cardiac-intimal-sarcoma-with-pdgfr%C3%AE-n666k-mutation
#5
Akihiro Nishiyama, Shigeki Sato, Hiroyuki Sakaguchi, Hiroshi Kotani, Kaname Yamashita, Koushiro Ohtsubo, Keishi Mizuguchi, Hiroko Ikeda, Kenji Iino, Hirofumi Takemura, Shinji Takeuchi
In the realm of rare cardiac tumors, intimal sarcoma presents a formidable challenge, often requiring innovative treatment approaches. This case report presents a unique instance of primary intimal sarcoma in the left atrium, underscoring the critical role of genomic profiling in guiding treatment. Initial genomic testing unveiled a somatic, active mutation in PDGFRβ ( PDGFRβ N666K), accompanied by MDM2 and CDK4 amplifications. This discovery directed the treatment course toward pazopanib, a PDGFRβ inhibitor, following irradiation...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38640125/xinnaotongluo-liquid-protects-h9c2-cells-from-h-r-induced-damage-by-regulating-mdm2-steap3
#6
JOURNAL ARTICLE
Jiankun Cui, Qinwen Wang, Minghao Li
Xinnaotongluo liquid has been used to improve the clinical symptoms of patients with myocardial infarction. However, the molecular mechanism of Xinnaotongluo liquid is not completely understood. H9c2 cells exposed to hypoxia/reoxygenation (H/R) was used to simulate damage to cardiomyocytes in myocardial infarction in vitro. The biological indicators of H9c2 cells were measured by cell counting kit-8, enzyme linked immunoabsorbent assay, and western blot assay. In H/R-induced H9c2 cells, a markedly reduced murine double minute 2 (MDM2) was observed...
2024: PloS One
https://read.qxmd.com/read/38637236/mandibular-rhabdomyosarcoma-with-tfcp2-rearrangement-and-osteogenic-differentiation-a-case-misdiagnosed-as-fibrous-dysplasia-or-low-grade-central-osteosarcoma
#7
Fu Chen, Junjia Wang, Yanan Sun, Jiali Zhang
Rhabdomyosarcoma with TFCP2-related fusions (TFCP2-RMS) is a rare entity that commonly affects young adults with a predilection for skeletal involvement. We herein report a 40-year-old female patient with TFCP2-RMS who was misdiagnosed as fibrous dysplasia or low-grade central osteosarcoma of the mandible by referring institutions. Histologically, the tumor showed dominant spindle cells and focal epithelioid cells with marked immature woven bone formation. Immunophenotypically, in addition to the characteristic expression of myogenic markers, ALK, and cytokeratins, tumor cells also unusually expressed osteogenic markers, such as MDM2 and SATB2...
January 11, 2024: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
https://read.qxmd.com/read/38631135/molecular-characterization-and-survival-analysis-of-a-cohort-of-glioblastoma-idh-wildtype
#8
JOURNAL ARTICLE
Bilge Dundar, Mouaz Alsawas, Amr Masaadeh, Kyle Conway, Anthony N Snow, Ramakrishna R Sompallae, Aaron D Bossler, Deqin Ma, Osorio Lopes Abath Neto
Glioblastoma, IDH-wild type, the most common malignant primary central nervous system tumor, represents a formidable challenge in clinical management due to its poor prognosis and limited therapeutic responses. With an evolving understanding of its underlying biology, there is an urgent need to identify prognostic molecular groups that can be subject to targeted therapy. This study established a cohort of 124 sequential glioblastomas from a tertiary hospital and aimed to find correlations between molecular features and survival outcomes...
April 5, 2024: Pathology, Research and Practice
https://read.qxmd.com/read/38627379/pole2-promotes-osteosarcoma-progression-by-enhancing-the-stability-of-cd44
#9
JOURNAL ARTICLE
Baichuan Wang, Hongzhi Hu, Xiaohui Wang, Zengwu Shao, Deyao Shi, Fashuai Wu, Jianxiang Liu, Zhicai Zhang, Juan Li, Zhidao Xia, Weijian Liu, Qiang Wu
Osteosarcoma (OS) is the most prevalent primary malignancy of bone in children and adolescents. It is extremely urgent to develop a new therapy for OS. In this study, the GSE14359 chip from the GEO database was used to screen differentially expressed genes in OS. DNA polymerase epsilon 2 (POLE2) was confirmed to overexpress in OS tissues and cell lines by immunohistochemical staining, qPCR and Western blot. Knockdown of POLE2 inhibited the proliferation and migration of OS cells in vitro, as well as the growth of tumors in vivo, while the apoptosis rate was increased...
April 16, 2024: Cell Death Discovery
https://read.qxmd.com/read/38623081/microfluidic-fabricated-liposomes-for-nutlin-3a-ocular-delivery-as-potential-candidate-for-proliferative-vitreoretinal-diseases-treatment
#10
JOURNAL ARTICLE
Elisabetta Esposito, Elena Pozza, Catia Contado, Walter Pula, Olga Bortolini, Daniele Ragno, Sofia Toldo, Fabio Casciano, Agnese Bondi, Enrico Zauli, Paola Secchiero, Giorgio Zauli, Elisabetta Melloni
PURPOSE: Proliferative vitreoretinal diseases (PVDs) represent a heterogeneous group of pathologies characterized by the presence of retinal proliferative membranes, in whose development retinal pigment epithelium (RPE) is deeply involved. As the only effective treatment for PVDs at present is surgery, we aimed to investigate the potential therapeutic activity of Nutlin-3a, a small non-genotoxic inhibitor of the MDM2/p53 interaction, on ARPE-19 cell line and on human RPE primary cells, as in vitro models of RPE and, more importantly, to formulate and evaluate Nutlin-3a loaded liposomes designed for ophthalmic administration...
2024: International Journal of Nanomedicine
https://read.qxmd.com/read/38621503/gli1-co-amplification-in-well-differentiated-dedifferentiated-liposarcomas-clinicopathologic-and-molecular-analysis-of-92-cases
#11
JOURNAL ARTICLE
Aarti E Sharma, Mark Dickson, Samuel Singer, Meera R Hameed, Narasimhan P Agaram
BACKGROUND: GLI1 (12q13.3) amplification is identified in a subset of mesenchymal neoplasms with a distinct nested round cell/epithelioid phenotype. MDM2 and CDK4 genes are situated along the oncogenic 12q13-15 segment, amplification of which defines well-differentiated (WDLPS)/dedifferentiated liposarcoma (DDLPS). The 12q amplicon can occasionally include GLI1 - a gene in close proximity to CDK4. We hereby describe the first cohort of GLI1/MDM2/CDK4 co-amplified WD/DDLPS. MATERIALS AND METHODS: The departmental database was queried retrospectively for all cases of WD/DDLPS having undergone next generation (IMPACT) sequencing with confirmed MDM2, CDK4, and GLI1 co-amplification...
April 13, 2024: Modern Pathology
https://read.qxmd.com/read/38617965/revealing-the-active-ingredients-and-mechanism-of-p-sibiricumm-in-non-small-cell-lung-cancer-based-on-uplc-q-tof-ms-ms-network-pharmacology-and-molecular-docking
#12
JOURNAL ARTICLE
Kaili Guo, Yu Jiang, Wei Qiao, Panpan Yuan, Miao Xue, Jiping Liu, Hao Wei, Bin Wang, Xingmei Zhu
The alcohol extraction of P. sibiricum has exhibited significant inhibitory effects on the production of free radicals and the proliferation of non-small-cell lung carcinoma (NSCLC) A549 cells. Despite the diverse components found in alcohol extraction of P. sibiricum and its multiple targets, the active components and associated targets remain largely unidentified. Hence, there is a need for additional investigation into the pharmacodynamic elements and mechanisms of action. This study aimed to analyze and identify the components responsible for the anti-tumor activity of alcohol extraction from P...
April 15, 2024: Heliyon
https://read.qxmd.com/read/38615585/mutational-landscape-of-oral-mucosal-melanoma-based-on-comprehensive-cancer-genomic-profiling-tests-in-a-japanese-cohort
#13
JOURNAL ARTICLE
Norihisa Ichimura, Yusuke Urata, Takeru Kobayashi, Hideharu Hibi
OBJECTIVES: Oral mucosal melanoma (OMM) is a rare but aggressive melanoma subtype. Due to its rarity, the genomic landscape of OMM remains unknown despite a relatively thorough understanding of the genetic profile of cutaneous melanoma (CM). In this study, we analyzed the genomic mutational profiles of Japanese patients with OMM and compared them with those of patients with nose/sinuses mucosal melanoma (NMM) and CM to identify potential therapeutic targets. MATERIALS AND METHODS: We extracted clinical and genomic information of patients with OMM (n = 15), NMM (n = 63), and CM (n = 413) who underwent comprehensive genomic profiling tests under the National Health Insurance between June 2019 and November 2023 from the Center for Cancer Genomics and Therapeutics database...
April 12, 2024: Oral Oncology
https://read.qxmd.com/read/38615061/imaging-features-of-perinephric-myxoid-pseudotumors-of-fat
#14
JOURNAL ARTICLE
Stephen M Broski, Jennifer A Knight, Brandon T Larsen, Andrew L Folpe, Doris E Wenger
OBJECTIVE: Retrospectively evaluate multimodality imaging features of perinephric myxoid pseudotumor of fat (PMPTF). METHODS: Institutional cases of PMPTF with CT, MRI and/or ultrasound evaluation from 1/1/2020 to 9/1/2023 were retrospectively reviewed. Patient demographics and clinical history were reviewed, and imaging features recorded. RESULTS: 14 patients with pathologically-proven PMPTF were identified (11 M, 3 F; mean age 66.7 ± 17...
April 13, 2024: Abdominal Radiology
https://read.qxmd.com/read/38612758/the-mdm2-p53-axis-represents-a-therapeutic-vulnerability-unique-to-glioma-stem-cells
#15
JOURNAL ARTICLE
Yurika Nakagawa-Saito, Yuta Mitobe, Keita Togashi, Shuhei Suzuki, Asuka Sugai, Senri Takenouchi, Kazuki Nakamura, Yukihiko Sonoda, Chifumi Kitanaka, Masashi Okada
The prevention of tumor recurrence by the successful targeting of glioma stem cells endowed with a tumor-initiating capacity is deemed the key to the long-term survival of glioblastoma patients. Glioma stem cells are characterized by their marked therapeutic resistance; however, recent evidence suggests that they have unique vulnerabilities that may be therapeutically targeted. We investigated MDM2 expression levels in glioma stem cells and their non-stem cell counterparts and the effects of the genetic and pharmacological inhibition of MDM2 on the viability of these cells as well as downstream molecular pathways...
April 2, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38602256/usp7-inhibitors-suppress-tumour-neoangiogenesis-and-promote-synergy-with-immune-checkpoint-inhibitors-by-downregulating-fibroblast-vegf
#16
JOURNAL ARTICLE
Anamarija Jurisic, Pei-Ju Sung, Mark Wappett, Julien Daubriac, Ian T Lobb, Wei-Wei Kung, Nyree Crawford, Natalie Page, Eamon Cassidy, Stephanie Feutren-Burton, J S Shane Rountree, Matthew D Helm, Colin R O'Dowd, Richard D Kennedy, Gerald Gavory, Aaron N Cranston, Daniel B Longley, Xavier Jacq, Timothy Harrison
BACKGROUND: Understanding how to modulate the microenvironment of tumors that are resistant to immune checkpoint inhibitors represents a major challenge in oncology.Here we investigate the ability of USP7 inhibitors to reprogram the tumor microenvironment (TME) by inhibiting secretion of vascular endothelial growth factor (VEGF) from fibroblasts. METHODS: To understand the role played by USP7 in the TME, we systematically evaluated the effects of potent, selective USP7 inhibitors on co-cultures comprising components of the TME, using human primary cells...
April 2024: Clinical and Translational Medicine
https://read.qxmd.com/read/38601081/revolutionizing-pediatric-neuroblastoma-treatment-unraveling-new-molecular-targets-for-precision-interventions
#17
REVIEW
Min Zheng, Ankush Kumar, Vishakha Sharma, Tapan Behl, Aayush Sehgal, Pranay Wal, Nirmala Vikram Shinde, Bhosale Sachin Kawaduji, Anupriya Kapoor, Md Khalid Anwer, Monica Gulati, Bairong Shen, Rajeev K Singla, Simona Gabriela Bungau
Neuroblastoma (NB) is the most frequent solid tumor in pediatric cases, contributing to around 15% of childhood cancer-related deaths. The wide-ranging genetic, morphological, and clinical diversity within NB complicates the success of current treatment methods. Acquiring an in-depth understanding of genetic alterations implicated in the development of NB is essential for creating safer and more efficient therapies for this severe condition. Several molecular signatures are being studied as potential targets for developing new treatments for NB patients...
2024: Frontiers in Cell and Developmental Biology
https://read.qxmd.com/read/38600316/combination-p53-activation-and-bcl-x-l-bcl-2-inhibition-as-a-therapeutic-strategy-in-high-risk-and-relapsed-acute-lymphoblastic-leukemia
#18
JOURNAL ARTICLE
Hayden L Bell, Helen J Blair, Samantha J Jepson Gosling, Martin Galler, Daniel Astley, Anthony V Moorman, Olaf Heidenreich, Gareth J Veal, Frederik W van Delft, John Lunec, Julie A E Irving
Due to the rarity of TP53 mutations in acute lymphoblastic leukemia (ALL), p53 re-activation by antagonism of the p53-MDM2 interaction represents a potential therapeutic strategy for the majority of ALL. Here, we demonstrate the potent antileukemic activity of the MDM2 antagonist idasanutlin in high-risk and relapsed ex vivo coculture models of TP53 wildtype ALL (n = 40). Insufficient clinical responses to monotherapy MDM2 inhibitors in other cancers prompted us to explore optimal drugs for combination therapy...
April 10, 2024: Leukemia
https://read.qxmd.com/read/38600177/hypoxia-treatment-and-resistance-training-alters-microrna-profiling-in-rats-skeletal-muscle
#19
JOURNAL ARTICLE
Tao Mei, Yang Hu, Ying Zhang, Yanchun Li
MicroRNAs (miRNAs) may play a crucial regulatory role in the process of muscle atrophy induced by high-altitude hypoxia and its amelioration through resistance training. However, research in this aspect is still lacking. Therefore, this study aimed to employ miRNA microarray analysis to investigate the expression profile of miRNAs in skeletal muscle from an animal model of hypoxia-induced muscle atrophy and resistance training aimed at mitigating muscle atrophy. The study utilized a simulated hypoxic environment (oxygen concentration at 11...
April 10, 2024: Scientific Reports
https://read.qxmd.com/read/38599733/primary-hepatic-pleomorphic-liposarcoma-case-report-and-literature-review
#20
Ligia Redrobán, Jorge Lara-Endara, Nelson Montalvo, Christian Armijos, Javier Rodríguez-Suárez, Frans Serpa
Primary hepatic liposarcoma is an extremely rare malignant tumour derived from adipocytes and is part of the group of mesenchymal tumours. We present the case of a 43-year-old Hispanic male patient with a pleomorphic hepatic liposarcoma and absence of MDM2 gene amplification. Two years and six months after surgery, the patient is asymptomatic. The present case is the first report of this entity with positive immunohistochemical testing for p16, p53, S100, vimentin and absence of MDM2 gene amplification.
2024: Revista Española de Patología
keyword
keyword
1695
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.